PINL:GRPOF - Post by User
Post by
ScienceGirlon Apr 03, 2018 2:45pm
221 Views
Post# 27822816
CEO leaving
CEO leaving
Really can't speculate as to why he left, but wouldn't the next CEO have it made for him? We do have financing secured which I think was the hard part. I just hope they get some really top notch talent for the next CEO to really drive this forward, it looks to me like they have the resources in place.
I also don't think that Fortier leaving should have any impact on Phase III starting for PP0001, as that has been planned to a T by now. The hold up with recruitment is typical, 90% of clinical trials go through these delays in Canada.
They even stated that they are working on approvals from the FDA to expand the study to the USA, which is a good proactive move to ensure they meet their recruitment targets in time. I've seen a whole bunch of studies think of this too late when they realize recruitment is slow in Canada after being a few months in. It is always slow due to the legal and ethical barriers that are more profound in Canada than in the USA, I won't get into detail now.
I do get a bit uneasy with changes, but if there was a time to make them then this is the right time. The next few steps are outlined for the new CEO, they have some time to get into it and work on new initiatives. This is all IMO, looking forward to hearing your opinions too.